Business · 09/03/2010Updated: 10/17/2026 · 1 min read
FDA Clears Path for Calcipotriene Ointment Approval
Summary
The FDA has determined that DOVONEX (calcipotriene) Ointment, 0.005%, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of generic versions.
Original source language: Federal Register — Health and Human ServicesOpen original release →